Tactile Systems Technology (NASDAQ:TCMD) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Tactile Systems Technology (NASDAQ:TCMD) released its quarterly earnings data on Tuesday. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.09, Zacks reports. Tactile Systems Technology had a return on equity of 9.24% and a net margin of 5.42%. Tactile Systems Technology updated its FY 2025 guidance to EPS.

Tactile Systems Technology Stock Up 3.1 %

NASDAQ TCMD traded up $0.53 on Tuesday, hitting $17.86. The stock had a trading volume of 413,672 shares, compared to its average volume of 247,992. Tactile Systems Technology has a 52-week low of $11.12 and a 52-week high of $21.10. The business’s fifty day moving average price is $17.45 and its 200 day moving average price is $15.61. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.37 and a quick ratio of 3.80. The stock has a market cap of $428.64 million, a price-to-earnings ratio of 27.48 and a beta of 1.20.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on TCMD shares. Oppenheimer downgraded shares of Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. StockNews.com cut Tactile Systems Technology from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 16th. Finally, BTIG Research downgraded Tactile Systems Technology from a “buy” rating to a “neutral” rating in a report on Tuesday, November 5th.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.